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Background: Methylmercury (MeHg) is a neurotoxin primarily found in seafood; exposures in reproductive-age
women are of concern due to vulnerability of the developing fetus. MeHg is mainly eliminated via an enterohepatic
cycle involving the liver and gallbladder. Dysfunction in these organs has been associated with slower MeHg
elimination in laboratory animals. We hypothesized that women testing positive for chronic hepatitis B (HBV) or C
(HCV), both associated with risk of longer-term liver and gallbladder impairment, would have higher total blood
mercury (TBHg) concentrations than those negative for the viruses, reflecting slower MeHg elimination.
Methods: Geometric mean (GM) TBHg levels from a representative sample of over 5,000 seafood-consuming,
reproductive-age women from eight years (2001–2008) of the US NHANES survey were compared by viral hepatitis
status (as determined by serological assay) using multiple linear regression. Adjustment was made for estimated
MeHg intake from seafood consumption, social and demographic variables and other predictors.
Results: Women with chronic HBV had 1.52 (95% CI 1.13, 2.05, p < 0.01) times the GM TBHg of women who had
not come into contact with the virus. The positive association was strongest in those with most severe disease. A
modest negative association was found with HCV markers.
Conclusions: While study design prevents inferences on causality, the finding that MeHg biomarkers differ by
hepatitis status in this population suggests viral hepatitis may alter the pace of MeHg elimination. Offspring of
HBV-infected seafood-consuming women may be at higher risk of MeHg-induced developmental delays than
offspring of those uninfected. Possible reasons for the unanticipated negative association with HCV are explored.
Keywords: Biomonitoring, Developmental neurotoxicity, Hepatitis, Mercury, NHANES, Reproductive-age women,
Seafood, SusceptibilityBackground
Methylmercury (MeHg) is a neurotoxin widely present
in the environment to which the developing fetus is
acutely vulnerable [1]. The primary exposure source and
pathway for this sensitive population is maternal seafood
consumption [2]. Numerous countries have issued com-
mercial seafood advisories for reproductive-age women
[3] with the goal of minimizing MeHg intake and* Correspondence: msheehan@jhsph.edu
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reproduction in any medium, provided the orprotecting offspring from the verbal, spatial and fine-
motor skill delays associated with MeHg-induced devel-
opmental neurotoxicity [2].
Individuals are known to differ in susceptibility to
health risks from contaminants such as MeHg [4,5].
Variability has been observed in MeHg’s toxicokinetic
processing as well as its neurotoxic effects in association
with differences in maternal age [6], genetic polymorph-
isms in the glutathione (GSH) system [7], nutrient intake
[8,9] and the social environment [10], among other fac-
tors. Further study of such effect modifiers has been
called for [11,12]. In particular, while substantialal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phase [1,13], few epidemiological studies have examined
factors that modify the pace of elimination. Infants born
to seafood-consuming reproductive-age women who are
slow eliminators of MeHg may be at higher risk of
neurological harm.
MeHg is eliminated primarily (more than two-thirds)
via the biliary pathway [14]. Animal studies have shown
that elimination of MeHg, like many nutrients, drugs
and xenobiotics, involves an enterohepatic (EH) cycle
[15]. According to Dutczak et al. [16]:
“Reabsorption of solutes from bile. . . functions to con-
serve endogenous compounds but can also prove deleteri-
ous by impeding the clearance of toxic compounds. . .
MeHg . . . [is] believed to undergo extensive enterohepatic
cycling. . . [in which] the gallbladder . . . reabsorbs MeHg
reducing the amount delivered to the GI tract, and there-
fore the amount that can be eliminated. . .”
EH reabsorption of MeHg helps explain its relatively
long half-life (averaging about 50–70 days) in the human
body [15,17]. Factors such as prescription drugs, age, and
disease have been observed to speed or slow the pace of
EH cycling [18,19]. In particular, it may be hypothesized
that dysfunction in the liver and gallbladder, key organs in
the EH cycle, may contribute to the wide variability in
MeHg half-life observed (from 32 to 189 days) [17]. Ex-
perimental research has found that depletion of GSH,
which can occur when the liver functions poorly,
decreased biliary excretion of MeHg and increased its
half-life in male rats [20]. In biliary excretion-deficient
male rats lower bile flow was associated with a 2.5-times
longer MeHg elimination time than in control animals
[21]. In humans, liver that is damaged by inflammation, fi-
brosis (hardened, fibrous tissue) or cirrhosis (replacement
of healthy by scar tissue) has a lower share of normally-
functioning tissue than healthy liver [22]; blood flow and
metabolism are reduced, metabolic byproducts may be
less efficiently transported into bile, and bile less efficiently
cleared [22,23]. Such conditions may affect hepatobiliary
clearance by decreasing uptake of substances into hepato-
cytes, changing metabolism in hepatocytes, or decreasing
elimination into bile [18].
The most common cause of liver disease is viral hepa-
titis [24,25]. In the US, 4.9% of the population has been
exposed to hepatitis B (HBV) and the prevalence of
chronic HBV is 0.3%; hepatitis C (HCV) exposure is
estimated to be 1.8% and prevalence of chronic disease
is 1.6% [25]. The common general characteristics of
both chronic HBV and HCV include premature death
of hepatocytes, inflammation, and fibrosis [26]. Up to
30% of HBV carriers and 65% of the HCV-infected go
on to develop cirrhosis (the highest stage of fibrosis)
and/or hepatocellular carcinoma (HCC) [24,27]. Chronic
hepatitis can also lead to structural changes in biliaryelimination architecture [18,27,28]. Specifically, viral
hepatitis has been associated with thickening of the gall-
bladder wall and development of gallbladder sludge
[29], presence of gallstones [30], and gallbladder and
bile duct polyps and cancers [31,32] in epidemiological
studies in varied populations. Bile acids, which also
undergo EH cycling, have been found to be elevated in
serum in cases of hepatitis-associated liver dysfunction
[27].
Based on this literature, we hypothesized that chronic
viral HBV or HCV could interfere with biliary elimin-
ation of MeHg, and that this would be reflected in
higher circulating blood levels of mercury in those with
these diseases compared to those without. As reference
scenarios, we further hypothesized no difference in
blood mercury concentrations between those with and
those without the acute-only and self-limiting hepatitis
A (HAV), and between those vaccinated and those un-
vaccinated for HBV.Methods
Study population and data
We tested this hypothesis in a large sample of
reproductive-age seafood-consuming women who partici-
pated in the National Health and Nutrition Examination
Survey (NHANES). NHANES is a complex, stratified
multi-stage sample designed to be representative of the
US non-institutional population, implemented by the
CDC’s National Center for Health Statistics (NCHS). Data
collection consists of an in-person interview to gather
demographic, socioeconomic and other information, and
a physical examination. The exam includes a dietary ques-
tionnaire and laboratory testing of blood, urine and other
tissue samples for a standard biochemical and disease
panel and numerous chemical toxicants. In order to have
a sufficient sample size to stratify by gender, lifestage, sea-
food intake, and hepatitis status, we pooled data from
2001 to 2008, the most recent four NHANES cycles with
full data available. The total screened sample for the eight-
year period was 50,822; the average response rate for the
interview was 80%, and for the exam was 77%. We ana-
lyzed data for 7,870 women aged 16–49 who completed
the NHANES questionnaire, examination and laboratory
components. We eliminated women who answered nega-
tively to having consumed seafood in the last 30 days (as
these women were less likely to have detectable blood
mercury concentrations), as well as those missing blood
mercury measurements and other covariates of interest.
The total number of study participants was 5,088 for the
HBV analysis; 5,071 for HCV; and 4,104 for HAV (HAV
assay results were available for 2001–2006 only).
Informed-consent was provided by all participants, and
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tional review board.Blood mercury measurement
The main dependent variable was the concentration of
total blood mercury (TBHg), a validated proxy measure
for recent MeHg intake [33,34]. TBHg was measured in
micrograms per liter (μg/L) of whole blood using cold
vapor atomic absorption spectrometry (2001–2002) and
inductively-coupled plasma dynamic reaction cell mass
spectrometry (2003–2008). Analysis of samples was
done at the CDC’s Division of Laboratory Sciences, Na-
tional Center for Environmental Health (NCEH). All
medical and phlebotomy staff were trained and used
standardized protocols. Other than measurement tech-
nique, no changes in lab procedures were noted over
the study period. Quality assurance included use of
blind split samples, repeat testing and use of inter-
national standard rules for quality control. NCEH staff
verified extremely high and low values and performed
consistency checks. The limit of detection was between
0.14 μg/L and 0.33 μg/L.
Determination of hepatitis status and study hypotheses
The main independent variable for this analysis was
hepatitis status. Hepatitis status was determined using
CDC case definitions [35,36], the hepatitis literature, and
hepatitis assay results for our 2001–2008 sample of
reproductive-age women (Table 1). For the women in
this NHANES sample, laboratory results analyzed by the
CDC’s Division of Viral Hepatitis were available for a
sub-set of the assays noted in the CDC chronic HBV
and HCV case definitions: hepatitis B core antibody
(anti-HBc); hepatitis B surface antibody (anti-HBs);Table 1 Hepatitis groups, available NHANES test results and n
Hepatitis group NHANES tests avai
Hepatitis A
Current or past infection or immunization An
No infection or immunization An
Hepatitis B
Current infection Anti-HBc p
- Active infection As for current
- Inactive carrier As for current
Resolved (past) infection HBsAg negative, a
Immunized HBsAg negative, an
No infection or immunization HBsAg negative, an
Hepatitis C
Current or past infection A
No infection Ahepatitis B surface antigen (HBsAg), and hepatitis C
antibody (anti-HCV). Results were also available for total
hepatitis A antibody (anti-HAVT). We examined three
models.
In the Hepatitis A model, comparison was made be-
tween women who tested positive for total hepatitis A
antibody (anti-HAVT) – which indicates current or past
exposure to either the HAV virus or the vaccine [24] –
and the reference (negative anti-HAVT) group. Anti-
HAVT was determined using a solid-phase competitive
enzyme-based immunosorbent assay (ELISA). Because
the acute-only HAV infection carries low risk of longer-
term liver damage, in this model we hypothesized there
would be no association between TBHg concentrations
and positive anti-HAVT status.
HBV has a more complex natural history, with four
recognized stages of disease: virus incubation, immune
response, recovery (inactive carrier status), and develop-
ment of immunity; while an average of 1-2% of inactive
carriers seroconvert and develop natural immunity an-
nually, about one-third may at some point re-activate to
active disease [24,26]. Positive anti-HBc accompanied by
positive HBsAg indicates chronic active disease, while in
combination with negative HBsAg it indicates likely in-
active carrier status. Anti-HBs is a marker of immunity;
in combination with anti-HBc this is likely to be natural
immunity, while anti-HBs positive alone signals probable
vaccine-derived immunity [24,26,37]. Based on these
serological assays we defined three HBV-exposed
groups:
 Current HBV: women positive for anti-HBc and
negative for anti-HBs, including both those HBsAg
positive (likely to have active disease) and those
HBsAg negative (likely to be inactive carriers);umber of women in study sample
lable and results to be in group No. women in sample
ti-HAVT positive 1,466
ti-HAVT negative 2,638
ositive, anti-HBs negative 40
infection, plus HBsAg positive 11
infection, plus HBsAg negative 29
nti-HBc positive, anti-HBs positive 145
ti-HBc negative, anti-HBs positive 1,520
ti-HBc negative, anti-HBs negative 3,383
nti-HCV positive 70
nti-HCV negative 5,001
Sheehan et al. Environmental Health 2012, 11:62 Page 4 of 11
http://www.ehjournal.net/content/11/1/62 Recovered HBV: women positive for both anti-HBc
and anti-HBs, denoting past infection and
development of natural immunity to the virus; and
 Immunized HBV: women positive for anti-HBs and
negative for anti-HBc, indicating vaccine-derived
immunity.
Each HBV-exposed group was compared to the refer-
ence group negative for anti-HBc, anti-HBs and HBsAg
(i.e., no contact with the virus or vaccine). Anti-HBc was
detected using an ELISA (Ortho) in which all reactive
specimens were re-tested (the result was positive with at
least one reactive re-test). Only positive anti-HBc sam-
ples were tested for HBsAg, detected using a sandwich
ELISA (Abbott Labs). Anti-HBs was determined using a
sandwich solid phase ELISA (AUSAB), with concentra-
tion of anti-HBs compared to a standard curve. Because
of the elevated risk of longer-term liver and gallbladder
damage we hypothesized a positive association between
presence of markers for current HBV and TBHg levels.
Since the seroconverted remain at elevated risk of devel-
oping fibrosis, cirrhosis and HCC over their lifetimes
[24], we also hypothesized an association between mar-
kers of HBV recovery and TBHg levels. We hypothe-
sized no association between having been vaccinated for
HBV and TBHg.
In model C, we compared women testing positive for
anti-HCV, indicative of current or past infection [24,26],
and the reference uninfected group. Anti-HCV was
detected using direct solid-phase ELISA screening, and
positives confirmed with recombinant immunoblot assay
(Chiron). Due to longer-term liver damage associated
with HCV, we hypothesized a positive association be-
tween presence of anti-HCV and TBHg concentrations.
There is currently no vaccine for HCV.
MeHg intake and other covariates
Seafood consumption frequency and species are the
main determinants of MeHg intake in the non-
occupational general human population [1,2,34]. The
NHANES dietary interview covered consumption fre-
quency of 10 shellfish and 21 finfish species (number of
servings over the 30 days prior to the interview). Trained
interviewers used a computerized data collection instru-
ment (involving a five-step recall process: quick list, for-
gotten foods prompt, time and occasion prompt, details
prompt, and final probe), along with aids such as photos
of different seafood species. Quality control included re-
confirming all values over nine servings and review of
interviewer audio reports, among other measures. We
used these seafood consumption data, along with sea-
food species-specific mercury concentration data pub-
lished by the US FDA [38], to calculate estimated MeHg
intake by study participant. MeHg intake for the sixmost frequently-consumed species was estimated by
multiplying the number of meals for each over 30 days
by per-meal mercury values in grams, derived using the
FDA average MeHg concentration for the species (as-
suming a 170-gram meal size [39]). To estimate MeHg
intake from less commonly-consumed other finfish and
shellfish we used average FDA MeHg concentration
values for all finfish and all shellfish, respectively. The
results were aggregated by participant and used to adjust
the three models for 30-day estimated MeHg intake
from seafood.
Additional independent variables that could potentially
confound results were defined based on the mercury lit-
erature [34,40-42]. These included household income,
education attainment, ethnicity, country of birth, alcohol
intake, and body-mass index (BMI). We adjusted each
model for other hepatitis viruses, and given co-infection
with human immunodeficiency virus (HIV) among some
hepatitis-infected groups [43], we also included HIV sta-
tus as a covariate.
Statistical methods
To facilitate use of linear regression methods, we log-
transformed the right-skewed TBHg distribution. We
employed the back-transformed geometric mean (GM)
as a summary statistic, and used 95% confidence inter-
vals (95% CIs) to describe variation. Using bivariate ana-
lysis, we summarized GM TBHg concentrations by
covariate, and participant characteristics by hepatitis sta-
tus. We used linear regression analysis to examine rela-
tionships between TBHg and hepatitis status defined by
the serological markers described. Regression coeffi-
cients were back-transformed from the log scale. Our
main outcome was the ratio of GM TBHg concentration
between women in the defined hepatitis-exposed group
to the respective unexposed reference group. A GM
TBHg ratio of greater than 1.0 indicated a positive asso-
ciation, and a GM TBHg ratio of less than 1.0 indicated
a negative association. Statistical significance was tested
using a two-tailed t-test with an alpha level of 0.05. We
adjusted each model for the covariates described using
backwards step-wise selection to eliminate covariates (p-
value cut-off of less than 0.10). In addition, we examined
interaction terms to test for effect modification, and per-
formed sensitivity analyses to examine assumptions
about seafood intake, the most important driver of
TBHg levels. In sensitivity analysis we also examined
clinical markers of liver function. We weight-adjusted all
analyses to account for over-sampling of under-
represented groups, and used Taylor series linearization
for variance estimation as recommended by NCHS. All
statistical analyses were performed in Stata (Stata Statis-
tical Software: Release 10, Statacorp, College Station,
TX, 2007).
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Blood mercury concentrations
The GM TBHg concentration in this population of
reproductive-age seafood-consuming women was 1.02
(95% CI 0.97, 1.08) μg/L (Table 2). Consistent with the
literature [34,40,42], unadjusted GM TBHg concentra-
tions were higher in older women, those of “Other”
(Asian, Pacific Islander and Native American) ethnicity,
the foreign-born, those with higher household income
and education attainment, and those with lower BMI.
Women who consumed 5–8 servings of seafood over
the month had GM TBHg concentrations almost two
times higher than those who consumed 1–4 servings.
Those who consumed 9 or more servings had GM
TBHg concentrations over two times higher than the 1–
4 serving group. There was a moderate correlation be-
tween TBHg and seafood servings (correlation coeffi-
cient 0.34). Compared to women without exposure to a
hepatitis virus, those positive for HAV had similar GM
TBHg concentrations. Those positive for HBV had 1.4
times higher GM TBHg concentrations, and those posi-
tive for HCV had 25% lower GM TBHg concentrations,
than those without exposure to a hepatitis virus.
Hepatitis A, B and C status
Of 4,104 women in the hepatitis A model, 1,466 were
positive for anti-HAVT, indicating vaccine-derived or
natural immunity (Table 3). Of 5,088 women in the
hepatitis B model, 40 were positive for anti-HBc and
negative for anti-HBs, comprising the current HBV
group; 145 were positive for both anti-HBc and anti-
HBs, constituting the recovered HBV group; and 1,520
were negative for anti-HBc and positive for anti-HBs,
comprising the immunized HBV group. Of 5,071 women
in the hepatitis C model, 70 were positive for anti-HCV.
The implied prevalence rates are consistent with the epi-
demiology literature [25].
Women having had HAV, or having been vaccinated
for it, did not differ by age, BMI or alcohol intake from
those who had not, however, they did differ by socioeco-
nomic parameters (Table 3). Women having come into
contact with the hepatitis B virus (including both
current and recovered disease) were on average older
(by 6 years) than those without HBV contact and more
likely to have lower income and lower education attain-
ment, be of Black or Other ethnicity, and be foreign-
born. HBV-positive women also ate slightly (10%) more
seafood than the sample average, and about 11% were
co-infected with HCV. Those positive for HCV were
older (by 10 years), and more likely to have lower in-
come and lower education attainment compared to
women who were negative for HCV. Unlike those posi-
tive for HBV, however, women positive for HCV were
more likely to be American-born, to be of mainly Whiteor Black ethnicity, and to consume more alcohol than
average. These women ate slightly less (13%) seafood
than average, and about 30% were co-infected with
HBV.
Seafood consumption
The GM seafood intake in our eight-year sample of
reproductive-age women was 3.56 (95% CI 3.48, 3.65)
servings over the month prior to the NHANES inter-
view. The six species most commonly consumed (the
greatest number of servings by the largest share of the
population) were, in order: shrimp, tuna (all types com-
bined), salmon, crab, catfish, and breaded fish (assumed
to be mainly pollock). These species represented 55% of
total seafood intake. With the exception of tuna, average
mercury tissue concentrations of these species do not
generally exceed 0.1 ppm in the US, and are not cau-
tioned against in the national commercial seafood advis-
ory to pregnant and reproductive-age women [39].
Remaining seafood intake was comprised of smaller
numbers of women consuming fewer servings spread
across 25 other species. The highest-mercury species (e.
g., swordfish) were consumed relatively rarely, by few
women. Each serving of seafood was associated with an
increase in GM TBHg of 6% for the whole sample, an
increase of 10% (p < 0.001) when considering women
with HBV, and a decrease of 6% (p = 0.28) for those with
HCV (results not shown).
Ratios of blood mercury concentration by hepatitis status
HAV Model A
In regression analysis we found no significant association
between HAV-positive status and GM TBHg concentra-
tions (Table 4). This did not change after adjusting for
estimated MeHg intake, household income, education
attainment, ethnicity, BMI, alcohol intake, age, country
of birth, and HBV and HCV status (GM TBHg ratio
1.02, 95% CI 0.92, 1.14 p = 0.67).
HBV Model
We found a statistically-significant positive association
between being in the current HBV group and GM TBHg
concentration (Table 4). The association remained after
adjusting for estimated MeHg intake, household income,
education attainment, ethnicity, country of birth, age,
BMI, alcohol intake, and HIV status (GM TBHg ratio
1.52, 95% CI 1.13, 2.05, p < 0.01). The interaction term
between seafood intake and chronic hepatitis was statis-
tically significant (p < 0.01). Regression results differed
for the two sub-groups with current infection: For the
active infection group the positive association after ad-
justment was stronger (1.99, 95% CI 0.94, 4.22, p = 0.07;
n = 11) than for the inactive carrier group (1.40, 95% CI
1.06, 1.88, p = 0.02; n = 29). The association with having
Table 2 Total blood mercury concentrations (μg/L) in study participants by selected covariates
n= 1 GM 95% CI 5th P 25th P 50th P 75th P 95th P
Total 5,189 1.02 (0.97, 1.08) 0.20 0.58 1.00 1.87 4.82
Age (yrs)
- 16 – 19 1,103 0.74 (0.67, 0.82) 0.20 0.40 0.77 1.40 3.10
- 20 – 29 1,404 0.88 (0.81, 0.94) 0.20 0.50 0.88 1.66 3.70
- 30 – 39 1,358 1.13 (1.02, 1.24) 0.20 0.60 1.10 2.20 5.80
- 40 – 49 1,324 1.14 (1.07, 1.22) 0.28 0.70 1.10 1.90 5.00
Ethnicity
- White 2,100 1.00 (0.92, 1.07) 0.20 0.53 1.00 1.85 4.89
- Mexican American 1,248 0.77 (0.71, 0.84) 0.20 0.49 0.80 1.30 2.91
- Other Hispanic 328 1.04 (0.84, 1.29) 0.20 0.66 1.09 1.90 3.59
- Black 1,285 1.08 (0.99, 1.17) 0.30 0.63 1.04 1.75 4.10
- Other 228 1.90 (1.62, 2.24) 0.40 0.90 2.03 3.60 8.50
Country born
- US 4,008 0.98 (0.92, 1.04) 0.20 0.54 0.95 1.70 4.45
- Foreign 1,180 1.28 (1.15, 1.42) 0.28 0.70 1.25 2.49 6.52
Household income (/yr)
- < $45,000 2,580 0.86 (0.80, 0.92) 0.20 0.50 0.82 1.54 3.64
- $45,000-$75,000 1,070 1.03 (0.95, 1.11) 0.23 0.60 1.00 1.80 4.90
- > $75,000 1,217 1.29 (1.19, 1.30) 0.30 0.60 1.27 2.30 5.82
Education
- < HS diploma 1,695 0.76 (0.70, 0.83) 0.20 0.40 0.75 1.39 3.30
- HS diploma 1,052 0.93 (0.85, 1.00) 0.20 0.50 0.90 1.60 4.01
- BA degree 1,496 1.02 (0.94, 1.11) 0.20 0.60 1.00 1.80 4.10
- > BA degree 944 1.37 (1.26, 1.49) 0.30 0.72 1.35 2.62 6.40
BMI (kg/m2)
- < 30 3,920 1.10 (1.03, 1.17) 0.20 0.60 1.10 2.00 5.16
- > = 30 1,706 0.89 (0.83, 0.95) 0.20 0.50 0.86 1.50 4.00
Alcohol (g/day)
- < 10 4,500 0.97 (0.91, 1.03) 0.20 0.53 0.93 1.71 4.50
- > = 10 683 1.29 (1.18, 1.42) 0.30 0.71 1.29 2.31 5.58
Seafood (/mo.)
- 1–4 servings 4,422 0.93 (0.88, 0.99) 0.20 0.52 0.90 1.62 4.17
- 5–8 servings 458 1.72 (1.55, 1.91) 0.41 0.90 1.76 3.01 7.52
- >/= 9 servings 198 2.08 (1.81, 2.39) 0.65 1.14 1.92 3.70 10.60
Hepatitis A
- No infection or immunization 2,669 1.03 (0.99, 1.07) 0.20 0.60 1.00 1.90 4.90
- Infection or immunization 1,484 1.04 (0.99, 1.05) 0.23 0.60 1.00 1.90 5.10
Hepatitis B
- No infection or immunization 4,957 1.01 (0.96, 1.07) 0.20 0.57 1.00 1.81 4.70
- Past or current infection 2 185 1.39 (1.16, 1.65) 0.20 0.70 1.30 3.80 6.90
- Immunization 1,673 1.08 (1.03, 1.13) 0.20 0.68 1.07 1.98 4.90
Hepatitis C
- No infection 5,055 1.03 (0.97, 1.09) 0.20 0.59 1.00 1.89 4.80
- Past or current infection 70 0.74 (0.55, 1.01) 0.20 0.40 0.85 1.60 3.40
1 Includes all models; sample sizes do not always sum due to missing values. HAV analysis 2001–2006 only.
2 Current HBV and recovered HBV groups combined.
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Table 3 Characteristics of study participants by hepatitis serological marker status
Hepatitis A Hepatitis B Hepatitis C
Anti-HAVT 1 Anti-HBc 2 Anti-HCV 3
Positive Negative Positive Negative Positive Negative
N = 1,466 2,638 185 4,903 70 5,001
Age (yrs) 30.5 29.0 36.6 30.5 40.9 30.5
Ethnicity (%)
- White 22% 51% 22% 41% 51% 40%
- Mexican American 49% 12% 15% 31% 13% 31%
- Other Hispanic 6% 4%
- Black 17% 30% 48% 24% 30% 25%
- Other 5% 4% 15% 4% 7% 4%
Country born (% US) 51% 94% 61% 76% 96% 78%
Household income (%)
- < $45,000/yr 63% 48% 72% 52% 85% 52%
- $45,000-$75,000/yr 20% 23% 17% 22% 11% 22%
- > $75,000/yr 17% 29% 12% 26% 5% 26%
Education (%)
- < HS diploma 45% 28% 29% 33% 38% 33%
- HS diploma 18% 21% 29% 20% 32% 20%
- BA degree 23% 30% 27% 29% 25% 29%
- > BA degree 13% 21% 16% 18% 4% 19%
BMI (%< 30) 68% 67% 64% 67% 66% 67%
Alcohol (% <10 g/d) 89% 87% 84% 87% 70% 87%
Seafood (GM servings) 3.5 3.6 4.0 3.5 3.2 3.6
Anti-HAVT+ (%) – – 53% – 48% –
HBV co-infected (%) 6% – – – 30% –
HCV co-infected (%) 2% – 11% – – –
1 Anti-HAV positive – current or past infection or immunization; anti-HAV negative - no infection or immunization; HAV analysis 2001–2006 only.
2 Anti-HBc positive – current or past (resolved) infection; anti-HBc negative – no infection.
3 Anti-HCV positive – current or past infection; anti-HCV negative – no infection.
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statistically significant (1.14, 95% CI 0.93, 1.39, p = 0.21).
We found a weak, non-significant positive association
with HBV vaccination (1.07, 95% CI 0.98, 1.16, p = 0.11)
after adjusting for the covariates described.
HCV Model
We found a modest negative association between GM
TBHg concentration and HCV (Table 4). The associ-
ation remained after adjusting for estimated MeHg in-
take, household income, education attainment, ethnicity,
country of birth, age, BMI, alcohol intake and HBV sta-
tus, and reached borderline statistical significance (GM
TBHg ratio 0.72, 95% CI 0.51, 0.99, p = 0.05).
Discussion
In this study of a large representative sample of
reproductive-age seafood-consuming American women
we found those with markers of current chronic HBV
infection had 1.52 times the adjusted blood mercuryconcentration of those never having had contact with
the HBV virus or vaccine. The finding was statistically
significant thus unlikely due to chance alone. Among
those with current disease, the GM TBHg ratio was 1.40
for inactive HBV carriers and 1.99 for those with active
HBV, the most severe form of disease in this sample.
Women with recovered HBV, the mildest HBV disease
state we examined, had 1.14 times the adjusted GM
TBHg concentration of the never-infected or vaccinated.
Although some strata were small, these results are sug-
gestive of an increasing strength of association with in-
creasing severity of disease which adds weight to our
finding. We found no significant association between
GM TBHg concentrations and either having (or being
vaccinated for) acute-only HAV or having been vacci-
nated for HBV, situations normally without longer-term
risk of damage to the liver or gallbladder. These findings
are consistent with our proposed explanation that dam-
age to hepatobiliary elimination structures induced by
chronic viral hepatitis could interfere with MeHg’s EH
Table 4 Ratio of geometric mean total blood mercury (GM TBHg) concentrations comparing study participants by
hepatitis group
Unadjusted Adjusted
Model/group N = GM TBHg Ratio 1 95% Conf. Int. p- value 2 GM TBHg Ratio 1 95% Conf. Int. p- value 2
Hepatitis A Model 3 (total n = 4,104)
- Infection or immunization 1,466 1.01 0.92, 1.11 0.786 1.02 0.92, 1.14 0.674
Hepatitis B Model 4 (total n = 5,088)
- Current infection 40 1.84 1.37, 2.46 0.000 1.52 1.13, 2.05 0.007
Active 11 4.17 1.90, 8.93 0.000 1.99 0.94, 4.22 0.072
Inactive 29 1.43 1.08, 1.90 0.014 1.40 1.06, 1.88 0.020
- Recovered infection 145 1.31 1.07, 1.59 0.009 1.14 0.93, 1.39 0.205
- Immunized 1,520 1.04 0.96, 1.14 0.270 1.07 0.98, 1.16 0.111
Hepatitis C Model 5 (total n = 5,071)
- Infection 70 0.72 0.53, 0.98 0.039 0.72 0.51, 0.99 0.049
1 Ratio of GM TBHg in the infected (or vaccinated) group compared to the reference group. Ratio of > 1.0 suggests positive and<1.0 suggests negative association.
2 Statistical significance tested using two-tailed t-test, alpha level of 0.05.
3 Adjusted for estimated MeHg intake, ethnicity, household income, education attainment, country of birth, alcohol intake, age, body-mass index, HBV and HCV
status. HAV analysis 2001–2006 only.
4 As for (c), except HBV and HCV status, and including HIV status.
5 As for (c), except HCV status.
Table 5 Liver enzymes (mean) measured in blood, by
hepatitis group
ALT AST ALP GGT Bilirubin Albumin
Units IU/L IU/L IU/L IU/L mg/dL g/dL
Hepatitis A
No infection or immunization 19.3 21.4 65.9 18.5 0.65 4.07
Infection or immunization 20.8 21.9 75.7 18.7 0.63 4.07
Hepatitis B
No infection or immunization 20.2 22.0 66.7 19.4 0.64 4.08
Current infection 24.2 24.2 72.4 24.1 0.62 3.92
- Active 22.3 24.5 88.0 21.0 0.65 3.71
- Inactive 24.8 24.0 66.6 25.2 0.61 3.99
Recovered infection 20.2 22.1 65.3 21.0 0.61 4.02
Immunization 18.9 21.6 65.3 16.4 0.67 4.14
Hepatitis C
No infection 20.0 21.7 66.9 19.1 0.64 4.08
Past or present infection 39.2 37.6 70.3 48.9 0.61 3.98
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reflected in higher concentrations of circulating TBHg.
The modest negative association (0.72, p = 0.05) we
observed between HCV-positive status and GM TBHg
concentration was inconsistent with our hypothesis.
However, a finding of different outcomes for HBV and
HCV is plausible scientifically. While we hypothesized
both HBV and HCV would lead to reduced MeHg elim-
ination into bile, the EH cycle can also be accelerated by
liver and gallbladder dysfunction reducing uptake into
hepatocytes or altering metabolism [18]. For example,
MeHg has been found to be eliminated more quickly in
laboratory animals with ligated cystic ducts, in which re-
absorption to the gallbladder is prevented [16]. Cirrhosis
– a more frequent longer-term outcome of HCV than of
HBV – has been shown to lead to reduced hepatic up-
take due to lower perfusion of cells [18]. Presence of
gallstones, associated in the epidemiological literature
with HCV but not HBV [30,31,44,45], has also been
associated with faster gallbladder emptying [46]. In a re-
cent study, flavonoligands of silymarin – which are
eliminated through an EH cycle in circumstances of nor-
mal liver health – were found not to undergo EH cycling
in HCV patients, whereas substantial EH cycling was
found in non-alcoholic fatty liver disease patients [47].
The authors hypothesized HCV-specific changes in
hepatobiliary function led to the observed absence of EH
cycling. Our HCV findings of lower adjusted MeHg
levels among HCV-infected women appear consistent
with this research.
To further assess possible reasons for the differing
findings for HBV and HCV we also examined six clinical
markers of liver function analyzed in the laboratorycomponent of NHANES: alanine transaminase (ALT),
aspartate transaminase (ALT), alkaline phosphatase
(ALP), gamma glutamyl transpeptidase (GGT), bilirubin
and albumin. In our sample, women with current HBV
had statistically significant higher ALP and lower albu-
min levels than those without HBV (Table 5). ALP is
observed to be higher in cholestatic conditions where
normal bile flow is blocked or interrupted [48]. Those
with HCV had statistically significant higher transamin-
ase, ALP and GGT levels. Lower hepatic GGT (which
may lead to higher serum GGT) has been associated
with faster MeHg elimination through the EH cycle in
laboratory animals [16]. In our sample, the magnitude of
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tion and presence of anti-HCV was strongest in those
with the highest serum GGT levels. These liver marker
data are suggestive of possible differences in biliary elim-
ination patterns between the HBV- and HCV-infected in
our sample. Of additional relevance to our findings, al-
cohol intake has also been associated with lower blood
Hg concentrations [15,49]. Women positive for HCV in
our sample had higher than average alcohol intake
(whereas those positive for HBV did not), suggesting a
further possible factor in the negative association
observed.
This study had several limitations. Its cross-sectional
design precludes inferences regarding causality. Mer-
cury is known to be hepatotoxic in high doses [1], and
this could explain the positive association found with
HBV infection. Studies in rats and seals have found
positive associations between Hg tissue concentrations
and levels of some liver enzymes, and have elucidated
oxidative stress and other mechanisms of mercury’s
hepatotoxicity [20,50]. In humans, clinical case reports
have found acute auto-immune hepatitis in association
with inorganic Hg overdose [51,52]. With regard to
MeHg, elevated standard mortality ratios were found
for liver conditions among male Minamata disease sur-
vivors in some studies [53,54], but not in others [55]. A
positive association between ALT levels and TBHg was
observed in a study of US adults, although causality
could not be determined due to the cross-sectional de-
sign [56]. As noted by several researchers, despite
MeHg’s extensive EH cycling and presence in the liver,
the scientific literature on its hepatotoxicity is limited
[20,50].
While we believe viral hepatitis-induced gallbladder
damage and ensuing alteration of MeHg’s EH cycle is
the more plausible explanation for both our HBV and
HCV findings, other factors we were unable to test may
contribute to explaining observed associations. For ex-
ample, MeHg is eliminated from the body as GSH-con-
jugates, and GSH depletion is known to reduce the pace
of MeHg elimination [15]. Several genetic polymorph-
isms for production of glutathione-s-transferase (GST)
have been associated with MeHg retention [7].
NHANES data for 2001–2008 did not provide data on
serum levels of GSH or GST genetic variants, therefore
these variables could not be tested in the analysis. It is
possible that mercury intake from other sources (e.g.,
elemental mercury from dental amalgams) may con-
found our analysis, since other Hg forms can be
reflected in TBHg measures [15]. Differences in MeHg
toxicokinetics below steady state intake can be import-
ant [13] and may play a role in our findings in this US
population with comparatively low MeHg exposures.
Data were not available to allow us to control for otherforms of Hg intake, however there is no a priori evi-
dence that women with chronic hepatitis would have
higher exposure to other Hg sources than those with-
out. Additional toxicokinetic factors may be involved.
For example, presence of chronic HBV may trigger re-
lease of stored MeHg in the liver thereby increasing its
circulation in blood, as has been hypothesized for tea
consumption [57].
It is also possible that Hg’s immunotoxic effects could
make exposed individuals vulnerable to viral hepatitis.
Animal studies have found chronic exposure to low
doses of MeHg initially depress immune function then
stimulate an auto-immune response [58]. Studies in a
human population in Brazil’s Amazon Basin found that
Hg immunotoxicity may be a factor in malaria infection
[59]. Neither HBV nor HCV is cytotoxic; liver damage is
thought to occur due to the response mounted by the
immune system [24,60]. The relationship between Hg
immunotoxicity and HBV in particular may warrant fur-
ther study.
Because of the potential for HBV reactivation, and the
blurred line between low-grade infection and recovering
disease [24], the inactive HBV carrier category in this
analysis may include some women with active infection.
In addition, HCV-RNA – a better indicator of chronic
HCV – was available for only a portion of our sample,
resulting in strata size too small for analysis. However,
we believe any possible disease misclassification is likely
to have been minor, and would not have had a signifi-
cant effect on results.
The fact that MeHg intake was estimated based on
seafood frequency and species data from a self-report
questionnaire is a drawback of study design. This limita-
tion is mitigated to some extent by the careful NHANES
survey design and implementation and use of quality
control measures described, and by the finding that sea-
food is among foods least prone to recall bias [34]. The
use of TBHg, a biomarker reflective of recent MeHg ex-
posure [15], is consistent with the one-month seafood
intake data available in NHANES. However, MeHg’s
half-life is on average closer to two months. To address
seafood data shortcomings, we performed several sensi-
tivity analyses. In light of higher reported seafood and
estimated MeHg intake in the current HBV group than
sample average, we ran our model excluding the three
observations in this group with highest estimated MeHg
intake. The current HBV group’s estimated MeHg intake
fell to near sample average and the adjusted GM TBHg
ratio was 1.40 (95% CI 1.07, 1.83, p = 0.02), broadly con-
sistent with our main HBV model findings (results not
shown). We also evaluated intake of the most
commonly-consumed seafood species and found pat-
terns across disease categories were not markedly
different.
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This study found that TBHg levels varied by hepatitis sta-
tus among American reproductive-age seafood-consum-
ing women, and the observed associations remained after
adjusting for estimated MeHg intake from seafood con-
sumption and other predictors. While limited by the con-
straints of a cross-sectional design, these results raise the
possibility that chronic viral liver disease may alter the
pace of MeHg hepatobiliary elimination in reproductive-
age women – and therefore also affect the risk of neuro-
toxicity to the developing fetus. The finding that
seafood-consuming reproductive-age women with
chronic hepatitis B had 1.52 times the blood mercury
concentrations as women having had no contact with the
virus is of public health relevance. In particular, it sug-
gests offspring of HBV-positive high seafood-consuming
women may be at higher risk of verbal, spatial and fine-
motor skill delays associated with MeHg-induced devel-
opmental neurotoxicity. The implications may be par-
ticularly relevant in populations where chronic HBV
prevalence and seafood intake are both high (such as US
women of Asian and Pacific Islands ethnicity [24,61]).
This representative US sample was ethnically and so-
cially heterogenous, therefore it is reasonable to consider
possible implications of generalizing the findings inter-
nationally. Higher TBHg levels are observed in a number
of regions – e.g., Southeast Asia, the Amazon Basin, and
the Arctic [3] – where HBV is also endemic [62,63]. Fur-
ther study of the impact of liver disease on MeHg elim-
ination is warranted, in both animals and humans.
Possible policy implications include enhancing risk-
communication through targeting of commercial sea-
food advisories, adding mercury testing to existing HBV
screening programs for reproductive-age women, and
enhanced high-risk population surveillance.
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